Researcher Studying Potential Trigger of Inflammation Through VF-Funded Grant

By Ed Becker
Director of Marketing and Communications

Vasculitis is a disease in which blood vessels are damaged due to inflammation. However, the source of the inflammation is often unclear, making the disease difficult to treat. Dr. Sonia Sharma is hoping her VF-funded study will yield valuable insight into the possible triggers and origins of an autoimmune response in vasculitis.

Dr. Sharma received a one-year, $50,000 research grant for her study, Metabolic dysregulation of pro-inflammatory responses in DADA2 vasculitis. She is the lead investigator, along with co-investigators: Rekha Dhanwani, PhD, Mariko Takahashi, PhD and Ian Mathews, PhD, who are all based at the La Jolla Institute for Immunology, California and Mohit Jain, MD, PhD, who is based at UC San Diego, California.

Finding the Trigger to the Smoking Gun

Although autoimmunity is complex, a high-level understanding begins with a basic understanding of the body’s immune system. Working properly, the immune system protects us from bacteria, viruses, and even cancer. However, in vasculitis, and other autoimmune illnesses, our biological firewall becomes the “invader” itself wreaking havoc on the body’s systems.

A key question for researchers like Dr. Sharma, is how to find the “trigger” that initiates an autoimmune response at a cellular level. Adenosine deaminase 2 deficiency (DADA2) is an inherited disorder which can cause vasculitis of medium-sized blood vessels. The disease is caused by mutations in the CECR1 gene, which encodes a key metabolic enzyme in the purine pathway. DADA2 was first discovered in 2014. DADA2 can present similarly to polyarteritis nodosa.

It is not clear how DADA2 leads to vasculitis, and there are currently limited treatment options. Dr. Sharma and colleagues have found that loss of adenosine deaminase 2 enzymatic activity can cause changes in cellular purine metabolism. This loss can also cause the accumulation

continued on page 3

Stay Up-To-Date with VF Disease Brochures and New VF Website

The VF begins the year with two of its most popular patient resources getting a make over, which includes a new look and updates to important medical information about vasculitis.

VF Disease Brochures
Possibly the most requested item by patients and medical professionals are the VF disease brochures.

Over the last eight months the VF has completed an overhaul of the brochures that were first introduced in 2006.

Each of the 18 disease-specific pamphlets were re-written by a vasculitis medical specialist to include the most relevant symptom, diagnostic, and treatment information.

The brochures are available in two formats. Printed hardcopies can be ordered from the VF Office. Brochures can be viewed or downloaded from the individual disease pages on the VF website.

continued on page 7
Dear Friends,

Thank you to all who donated in support of our 2018 Annual Appeal “Join Our Journey”. With your support, we will focus on the critical first step of the journey, which is to help physicians recognize vasculitis as early as possible.

As part of our ongoing Recognizing Excellence in Diagnosis (V-RED) campaign, we are accepting applications for our 2019 awards program. Since its inception in 2014, patients worldwide have been able to nominate a medical professional they wanted to recognize for making a critical, early diagnosis of vasculitis. We are always interested in how health care professionals learn about vasculitis and utilize that knowledge to quickly recognize the signs and symptoms in their patients. Learn more on page 6.

We were also pleased to offer our first-ever VF educational conference in the Pacific Northwest. On January 12, 2019, over 100 patients, family members, physicians, and researchers from 11 states and numerous provinces in Canada, joined us for a one-day regional conference in Seattle, Washington.

Rare Disease Day February 28, 2019: Show Your Stripes!
Each year on the last day of February, the rare disease community comes together for Rare Disease Day to raise awareness of the challenges faced by the millions of people throughout the world who are impacted by rare diseases. This year, to honor the zebra— which is the official symbol of rare diseases in the United States— we encourage you to join the call to action “Show us YOUR Stripes”. Please share your stripes by posting your photos to social media using the hashtags: #showyourstripes #rarediseaseday.

This year we continue our partnership with the National Organization for Rare Disorders (NORD) to advocate for increased funding for research at the National Institutes of Health, ensuring access to affordable treatment, telemedicine, Medicare protection, and patient assistance programs. Through this partnership, we hope to encourage passage of these policies and the development of additional ones designed to improve patient experiences, outcomes, and ultimately, quality of life.

Join Us at Our Programs
We have one more regional conference at Mayo Clinic in Phoenix on March 9, and then our 2019 International Vasculitis Symposium July 19-21 in Bloomington-Minneapolis, Minnesota. We hope you will join us for one of these amazing conferences.

Sincerely,
Joyce A. Kullman
Executive Director
Paul Monach in New Role at Brigham and Women’s Hospital

By Ed Becker

In September 2018, Paul Monach, MD, PhD, joined Brigham and Women’s Hospital (BWH) in Boston, Massachusetts. He is the director of their new Vasculitis Center in the Department of Rheumatology, Immunology, and Allergy.

It’s a circular career move taking Monach back to the roots of his training as a rheumatologist. He completed his residency and rheumatology fellowship at BWH.

Monach’s specialization in vasculitis began in 2007 in the Section of Rheumatology at the Boston University School of Medicine and Boston Medical Center. He became the director of that vasculitis center in 2011. Since 2014, he has also been chief of the Rheumatology Section of the VA Boston Healthcare System.

According to Monach, he made the move for two reasons. “The move in large part was personal. I trained at BWH and have stayed in touch and already knew almost everyone there. Even 11 years later, it was the only place I would consider moving to, since moving would mean I would have to leave the great community of people who I have worked with at BU. The second reason was that I am able to do the same types of things I have been doing—taking care of patients with vasculitis and doing collaborative research—but I expect it will be easier to do so, for a few reasons.”

According to Monach, BWH has a particularly strong research enterprise in laboratory-based immunology, which he expects will take his research in new directions.

“BWH has a larger population of patients with giant cell arteritis and more use of advanced imaging (ultrasound and PET scanning) to evaluate them.” BWH is historically a prominent and successful institution in rheumatology (it started as a separate hospital for arthritis diseases), including clinical care, clinical research, and lab research, but it has never had anyone focus on vasculitis. I’m looking forward to adding that new area of expertise.”

Trigger of Inflammation, cont.

of purine metabolites, which are bio-active molecules that modulate inflammatory responses at the cellular level. Excessive purines can lead to an over-exaggerated inflammatory response in both vascular endothelial cells and immune cells.

The hope is that by studying DADA2, it will lead to understanding of what triggers an immune response in vasculitis.

“When we started out on this project we were initially focused on the role of the immune system, particularly in the innate or early arm of the immune response,” explains Dr. Sharma. “We very quickly zeroed in on the vascular endothelial cell, which is directly damaged in autoimmune vasculitis, as kind of a potentially new cellular mediator or driver of immune responses.”

She says that when studying the origins of inflammatory signals, she and her team want to focus on vascular endothelial cells in particular, because they might not only be damaged in autoimmune diseases like vasculitis, but, they may also be participating in the harm.

“Perhaps with several vasculitis syndromes, we need to not only look at immune cells as the source of the problem, but perhaps also the vascular endothelium as a potential driver or origin of pathological inflammation, or alternatively as an amplifier of the inflammatory reaction,” explains Dr. Sharma.

Blocking the Inflammatory Response

Ultimately, Dr. Sharma says, the goal would be to develop and design a specific treatment to alleviate, or re-normalize, abnormal purine metabolism in the vascular endothelium.

“So at the very early stages of our study, we are looking at several FDA-approved drugs that directly modulate the purine pathway. The hope would be that by correcting the metabolic dysregulation in vascular endothelial cells, as well as in the other immune cells, we can alleviate the source of the pathogenic inflammation,” says Dr. Sharma.

Dr. Sharma’s research team at La Jolla Institute for Immunology (LJI)
(l-r) Kay Foos, Yulia Kushnareva, Sonia Sharma, Ian Mathews, Rekha Dhanwani, Mariko Takahashi, Quinn Bui
Continuing Our Journey in the New Year

By Beth Westbrook
VF Director of Development

Welcome 2019!

It’s hard to believe we’re this far into the new year.

Before we get too far into 2019, I want to thank you for your generous support of the VF during 2018. It isn’t about the size of the gift, but the spirit in which it is given. Your generous support helped us launch numerous programs, including the 2018 launch of the “Join Our Journey” program.

We have lofty goals for 2019 and beyond. You have put your trust in us to lead the community to meet these goals.

During the first year of Join of Journey, we focused on early diagnosis with the Pathways to Diagnosis initiative. At the Los Angeles Regional Conference, one of the speakers said, “The average length of time to achieve a vasculitis diagnosis is three years.” That is unacceptable! In 2019, we will continue to reach out and support evidence-based projects that lead to an earlier diagnosis. Thanks to you – your gifts will continue our steps on this critical part of the journey.

The challenge we face going forward will be to keep up the momentum, and continue to generate critical funds and ongoing support.

One of my goals for this year is to build a sustainable volunteer program. Whether you like to write, fundraise, organize, or work at an event, we know the growth of the VF can be enhanced by volunteers. In the coming months, we will establish volunteer opportunities on our website. You may consider being a one-time volunteer or an ongoing volunteer.

Thank you. Simple words full of gratitude from all of us here at the Vasculitis Foundation. Be assured, your support makes all the difference in what we can achieve. I am grateful for all that was done in 2018, however, I’m restless to achieve the goal of early diagnosis, more effective treatments, and finding a cure for vasculitis.

May peace, joy, happiness, and good health follow you throughout 2019.

Seattle Patient Conference a Success

On Saturday, January 12, over 100 patients with vasculitis, their family members, and other guests attended the Vasculitis Foundation Patient Conference at the Crowne Plaza Seattle Airport Hotel in Seattle, Washington. The event, the first ever in this region, was held in partnership with the University of Washington Medical Center. The conference was made possible through grants from Celgene, Genentech and GSK.

The conference kicked off with the presentation, Vasculitis Update: What’s New for Patients, led by Phillip Seo, MD, Associate Professor of Medicine Director, The Johns Hopkins Vasculitis Center. Five additional presentations rounded out the day: Lung Involvement in Vasculitis, Fast Track Clinics for Giant Cell Arteritis at University of Washington, Staying Healthy in Spite of Having Vasculitis, and Rarer Forms of Vasculitis.

Following a panel Q&A session, professional violinist, and VF Board of Director’s member, Allison Lint, ended the day with a musical performance.

To view more photos from the Seattle Conference, visit VasculitisFoundation.org

Photos courtesy of Andy Starnes/ Vasculitis Foundation
Join Us For Our Vasculitis Foundation Patient Conference

PHOENIX, AZ
Saturday, March 9, 2019

Vasculitis Foundation and Mayo Clinic Arizona Present:
2019 Vasculitis Foundation Phoenix Patient Conference
Mayo Clinic Education Center - Waugh Auditorium
5777 East Mayo Boulevard, Phoenix, AZ 85054

$40 registration fee; $25 VF member registration fee I DEADLINE March 4, 2019
Call to Register: 816-436-8211 Ext:1 or go to: https://bit.ly/2DgOk6P

Preliminary Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 a.m.</td>
<td>Check-In/Registration</td>
</tr>
<tr>
<td>9:15 a.m.</td>
<td>Light Continental Breakfast</td>
</tr>
<tr>
<td>9:15 a.m.</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td>Rodrigo Cartin-Ceba, MD</td>
</tr>
<tr>
<td></td>
<td>Pulmonary and Critical Care Medicine</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic Arizona</td>
</tr>
<tr>
<td>9:30 a.m.</td>
<td>Large Vessel Vasculitis</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Kenneth J. Warrington, MD</td>
</tr>
<tr>
<td></td>
<td>Chair, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Lung Involvement in Vasculitis</td>
</tr>
<tr>
<td>10:30 a.m.</td>
<td>Rodrigo Cartin-Ceba, MD</td>
</tr>
<tr>
<td></td>
<td>Pulmonary and Critical Care Medicine</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic Arizona</td>
</tr>
<tr>
<td>10:30 a.m.</td>
<td>Morning Break</td>
</tr>
<tr>
<td>10:45 a.m.</td>
<td>Advances in Treatment of ANCA-Associated Vasculitis</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Ulrich Specks, MD</td>
</tr>
<tr>
<td></td>
<td>Chair, Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, Minnesota</td>
</tr>
<tr>
<td>11:15 a.m.</td>
<td>Upper Airway Involvement in Vasculitis</td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td>David G. Lott, MD</td>
</tr>
<tr>
<td></td>
<td>Division of Otolaryngology, Mayo Clinic Arizona</td>
</tr>
<tr>
<td>11:45 a.m.</td>
<td>Vasculitis Patient-Powered Research Network (V-PPRN)</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Kalen Young, MA</td>
</tr>
<tr>
<td></td>
<td>V-PPRN Network Manager</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Lunch: Patient Experience Story</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Suzanne DePaolis</td>
</tr>
<tr>
<td></td>
<td>VF Board of Directors, President-Elect</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Kidney Involvement in Vasculitis</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Alicia Rodriguez-Pla, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Arthritis Center, University of Arizona</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>New Biologicals for Asthma Management</td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>Matthew A. Rank, MD</td>
</tr>
<tr>
<td></td>
<td>Chair, Division of Allergy and Immunology, Mayo Clinic Arizona</td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>Managing Long-Term Corticosteroid Therapy</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Speaker to be announced</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Wrap-Up and Thank You</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>Rodrigo Cartin-Ceba, MD, MD</td>
</tr>
<tr>
<td></td>
<td>Joyce A. Kullman, Executive Director, Vasculitis Foundation</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>Dessert Reception</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td></td>
</tr>
</tbody>
</table>

The Phoenix Patient Education Regional Conference is made possible by grants from Celgene and Genentech.

Call to Register: 816-436-8211, Ext. 1
CME Course

Pre-Symposium
Vasculitis: Multidisciplinary Care for Multisystem Diseases Symposium

May 15, 2019 ~ Global Center for Health Innovation, Cleveland, Ohio

Editor Note: This event is for health care professionals.

Overview
Healthcare providers are invited to attend the Pre-Symposium Event, Vasculitis: Multidisciplinary Care for Multisystem Diseases Symposium. Attend for an update on the multisystem nature of vasculitic diseases and the role of multidisciplinary collaboration in patient care. Experts from diverse medical specialties will discuss how specific disease features can impact the approach to the diagnosis and management in vasculitis.

Learning Objectives
Healthcare providers will learn about recent advances in the treatment of granulomatosis with polyangiitis and the impact of lung and kidney involvement on management.

A discussion will be held on therapeutic approaches used for asthma and other features of eosinophilic granulomatosis with polyangiitis and how to differentiate this disease from other causes of hypereosinophilia.

Identify the immunosuppressive treatment options in giant cell arteritis, the role of imaging in its diagnosis and follow-up, and the spectrum of nonvasculitic disease that can affect the large vasculitic vessels.

Discuss the presentation, differential diagnosis, and treatment of cutaneous vasculitis.

Who Should Attend
This symposium is directed towards rheumatologists, nephrologists, pulmonologists, dermatologists, neurologists, and associated allied health practitioners interested in vasculitis.

For more information go to: https://bit.ly/2SyoyTW

V-RED Campaign Begins Its Sixth Year

By Ed Becker

Once again, the VF is accepting applications for its 2019 Recognizing Excellence in Diagnosis (V-RED) awards program. Since its inception in 2014, hundreds of patients worldwide have nominated a medical professional for making a critical, early diagnosis of vasculitis.

V-RED and Improving Awareness about Earlier Diagnosis
This unique recognition program is a perfect fit with the VF’s goal of helping to improve the rate of early diagnosis that’s part of the Join Our Journey program. By recognizing medical professionals who made a critical, often life-saving diagnosis of vasculitis, it helps raise awareness within the medical community, or among a doctor’s peers.

Last year, a record number of patients nominated their medical professionals. One winning doctor was chosen, and three others were awarded Honorable Mention status. All of the physicians nominated received a special certificate from the VF.

The VF also elevated awareness of the V-RED award through local, regional, and national media coverage.

How the V-RED Award Originated
The idea for the V-RED Award originated with VF Board Member, Karen Hirsch, whose son, Michael, was diagnosed with GPA/Wegener’s in 2011 by Juanita Mora, MD, an allergist/immunologist at the Chicago Allergy Center.

“I followed my gut and ordered further testing,” says Dr. Mora. “The labs and CT of his chest confirmed the diagnosis of GPA/Wegener’s. Michael received prompt treatment. The early diagnosis was critical and lifesaving in the preservation of his healthy organs and getting him in to remission.”

continued on page 11
CME Course

Plan on Attending Vasculitis 2019
The 19th International Vasculitis and ANCA Workshop
The Workshop is the premier academic meeting in the field of vasculitis. Investigators from around the world share data and discuss approaches to clinical, translational, and basic science research in all forms of vasculitis. There are also sessions on state-of-the-art clinical care. The Workshop is designed to address the interests of experienced clinicians and investigators, as well as those new to the field.

For more information go to: https://bit.ly/2TREMoK

Date & Location
› April 7 - 10, 2019
› Philadelphia, Pennsylvania

Course Overview
Designed by experts in the field, this one-day program will profile and discuss the recent advances made in the diagnosis and management of various forms of vasculitis, including giant cell arteritis, Takayasu’s arteritis, ANCA-associated vasculitis (granulomatosis polyangiitis and microscopic polyangiitis), eosinophilic granulomatosis with polyangiitis syndrome, Behçet’s disease, central nervous system vasculitis, and others. Each presentation will highlight the latest research advances and provide attendees with a clear understanding of the current standard of care for treatment of these challenging diseases.

Target Audience
› Dermatology
› Internal Medicine - Nephrology
› Internal Medicine - Rheumatology

Credits
› Ama Pra Category 1 Credits™ (6.75 Hours)
› Non-Physician Attendance / Participation (6.75 Hours)
› Abim Moc Part 2 (6.75 Hours)

For more information go to: https://bit.ly/2SJGX18

New Resources in 2019, cont.

The New VF Website - Coming Soon
If you visit the VF website expecting to see something familiar—you may be in for a surprise.

The site has a completely new look that’s designed to be more user-friendly, and easier to navigate.

Many of the most popular features from the old site, such as disease-specific information, locating medical specialists, or video archives, are still accessible, but they’re presented in a new way.

Enhancements include:
› The latest clinical information for all 18 vasculitic diseases.
› Updated listing of vasculitis specialists and centers throughout the world.
Glucocorticoid Elimination Works For 2/3 Of RA Patients On Tocilizumab

By Mitchel L. Zoler, Rheumatology News

CHICAGO – Nearly two-thirds of rheumatoid arthritis patients who achieved remission or low disease activity on tocilizumab plus low-dose prednisone were able to taper off prednisone treatment while remaining in at least low disease activity in a multicenter, randomized trial with 259 patients.

The results also showed that rheumatoid arthritis (RA) patients randomized to maintain prednisone treatment at 5 mg/day along with tocilizumab fared even better. After 24 weeks of the glucocorticoid-tapering regimen, by which time patients in the tapered arm had their prednisone dosage down to 0 mg, the average change from baseline in their disease activity score 28 with erythrocyte sedimentation rate (DAS28-ESR) was an increase of 0.538, compared with an average drop of 0.075 among untapered patients, a statistically significant difference for the study’s primary endpoint, Gerd R. Burmester, MD, said at the annual meeting of the American College of Rheumatology.

But while the results definitively showed that RA patients treated with the anti-interleukin 6 agent tocilizumab (Actemra) as their primary drug benefited from continued, additional treatment with low-dose prednisone, the results also showed that many patients could come off prednisone without immediate downside.

These findings "have potential to inform clinical practice and aid in conversations with patients. RA patients who achieve at least low disease activity while receiving tocilizumab and long-term glucocorticoid treatment at 5 mg/day should be considered for tapering of their glucocorticoid dosage, ideally targeting discontinuation," Dr. Burmester said.

Read the full article at: https://bit.ly/2CkLJYZ

IgA Vasculitis Linked To Higher Risk For Hypertension, Chronic Kidney Disease

By Jason Laday, Healio.com

Patients with IgA vasculitis, also known as Henoch-Schönlein purpura, are at an increased risk for hypertension and chronic kidney disease compared to those without the condition, according to recent findings in the Annals of the Rheumatic Diseases.

"IgA may be complicated by glomerulonephritis and it is thought that adult-onset IgA is associated with increased risk and severity of renal involvement compared with childhood disease," Lorraine Harper, PhD, MRCP, of the University of Birmingham, in the United Kingdom, and her colleagues wrote. "However, long-term health outcomes of adult-onset IgA are not well characterized."

Harper and her colleagues included 2,828 patients with adult-onset IgA vasculitis in their study, and matched them based on age and sex with 5,655 control participants. A total of 10,405 patients with childhood-onset IgA vasculitis were also included, and matched to 20,810 control participants.

"These findings emphasize the importance of blood pressure and renal function monitoring in patients with IgA [vasculitis]," they wrote. "Our data also suggest that IgA [vasculitis] should not be considered a ‘single hit’ disease, but that clinicians should monitor for long-term sequelae."

Further research is required to clarify the cause of hypertension in patients with IgA [vasculitis], and to investigate whether such patients suffer from additional long-term sequelae than that are currently unrecognized."

```
Our data also suggest that IgA [vasculitis] should not be considered a ‘single hit’ disease, but that clinicians should monitor for long-term sequelae.
```
Evaluation of Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis

Now Enrolling Patients

Primary Objective:
To evaluate the efficacy of sarilumab in patients with giant cell arteritis (GCA) as assessed by the proportion of patients with sustained remission for sarilumab compared to placebo, in combination with a corticosteroid (CS) tapering course.

› Ages Eligible for Study: 50 Years and Older
› Sexes Eligible for Study: All

Inclusion criteria:
› Diagnosis of giant cell arteritis (GCA) according to European League Against Rheumatism/American College of Rheumatology classification criteria.
› New onset active disease or refractory active disease.
› At least one of the symptoms of GCA within 6 weeks of baseline.
› Either erythrocyte sedimentation rate ≥30 mm/hour or C-reactive protein ≥10 mg/L within 6 weeks of baseline.
› Receiving or able to receive prednisone 20-60 mg/day for the treatment of active GCA.

For the full study description, design, full inclusion and exclusion criteria, and enrolling sites around the United States, please visit: https://clinicaltrials.gov/ct2/show/NCT03600805

If you do not have Internet access, please contact the VF office for a study flyer: 800.277.9474

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Now Enrolling Patients

Primary Objective:
To evaluate the efficacy of KEVZARA (sarilumab) in patients with polymyalgia rheumatica (PMR) as assessed by the proportion of subjects with sustained remission for sarilumab with a shorter corticosteroid (CS) tapering regimen as compared to placebo with a longer CS tapering regimen.

› Ages Eligible for Study: 50 Years and Older
› Sexes Eligible for Study: All

Inclusion criteria:
› Diagnosis of polymyalgia rheumatica (PMR) according to European League Against Rheumatism/American College of Rheumatology classification criteria.
› Patients must be on prednisone of at least 7.5 mg/day (or equivalent) and not exceeding 20 mg/day at screening and during the screening period.
› Patient is willing and able to take prednisone of 15 mg/day at randomization.
› Patients must have a history of being treated for at least 8 weeks with prednisone at a dose that is ≥7.5 mg/day (or equivalent) within the past 12 Weeks prior to screening.
› Unequivocal symptoms of PMR flare include shoulder and/or hip girdle pain associated with inflammatory stiffness.
› Patients must have erythrocyte sedimentation rate ≥30 mm/hr and/or C-reactive protein ≥10 mg/L associated with PMR disease activity within 12 weeks prior to screening.

For the full study description, design, full inclusion and exclusion criteria, and enrolling sites around the United States, please visit: https://clinicaltrials.gov/ct2/show/NCT03600818

If you do not have Internet access, please contact the VF office for a study flyer: 800.277.9474
**VF-Funded Study Publishes Results**

By Dario A. Leone, PhD

The group of Professor Renate Kain, MD, PhD, head of the Department of Pathology of the Medical University of Vienna (https://www.meduniwien.ac.at/hp/pathologie/) and Principal Investigator of an international research group working on renal pathalogy and immunology published a manuscript on the potential role of LAMP-2 (Lysosomal Associated Membrane Protein -2) in immunity and autoimmunity in The Journal of Immunology.

The study explored the role of LAMP-2 in the presentation of antigens, a mechanism by which highly specialized immune cells termed antigen presenting cells (APC) display on their surface portion of molecules that are sampled during their constant patrolling of all tissues.

The antigens derived from pathogens are recognized by T and B lymphocytes that can react to them and initiate an immune response, while antigens derived from tissue recognized as “self” are tolerated and should not induce an inflammatory event. Alterations of this fine-tuned system are the main cause of autoimmune disease, a group of illness in which – as one cause of diseases - T and B lymphocytes miss-interpret the signals from the APC and react against healthy cells inducing cell death and generating auto-antibody.

The research group of Professor Kain and Professor Andrew J. Rees initially reported the presence of autoantibodies directed against LAMP-2 in a high proportion of patients affected by renal vasculitis and that the generation of these autoantibodies may due to molecular mimicry with a bacterial protein, called FimH.

However the mechanisms leading to autoimmunity remained to be determined and consequently Dario A. Leone, MD, investigated whether the circulating anti-LAMP-2 antibodies influence the immune system. He analyzed their effect on human APC and found that antibodies specific for LAMP-2 are efficiently internalized by the APC and traffic to the antigen processing compartment.

Antigens from different sources were then chemically cross-linked to the anti-LAMP-2 abs to quantify their processing rate and to monitor the response of T lymphocytes. Surprisingly, antigen internalized by the LAMP-2 pathways were not “conventionally” processed and displayed on the surface of APC but were maintained in a more native condition and sorted into vesicles that were secreted extracellularly.

These extracellular vesicles termed “exosomes” are thought to serve as “long distance communication” they are equipped with proteins and specific molecules that are able to shape the immune system and they can travel in the blood stream to through the body. Therefore, exosomes currently constitute a “hot” research topic because of their potential application in drug delivery, vaccine strategy and cancer immunotherapy and up to date LAMP-2, is the first immune receptor that was shown to specifically divert antigens into exosomes, thus modulating T lymphocyte response.

**Dolly’s Story: Quick Diagnosis Gives 20+ Years**

*Editor’s note: This story is adapted from an essay that Dolly Espinoza wrote about being diagnosed with Wegener’s. Dolly’s husband shared it with us after her death.*

My name is Pete M. Espinoza. My wife, Dolly, was a Wegener’s patient who, sadly, passed away on April 29, 2018.

Dolly was diagnosed in 1996 and lived with the disease for 22 years. We were living in Idaho when she became ill with flu-like symptoms - feverish and weak, with body aches. Dolly made an appointment with Dr. Margo Saunders and she prescribed medications. But, after no improvement, she hospitalized Dolly for tests, including one for her kidneys.

After the test results came back, Dr. Saunders told us that she believed Dolly had Wegener’s granulomatosis (now GPA) and prescribed Cytoxan and prednisone. A rheumatologist at the University of Utah Medical Department agreed with the Wegener’s diagnosis and added Methotrexate to her drug regime. She always considered herself fortunate that she was diagnosed in a short amount of time.

Over the next 20+ years Dolly suffered kidney failure, dialysis, a kidney transplant, and other health issues. Ultimately, she contracted leukemia and passed away.

Learning about vasculitis was frightening, especially since Dolly had never been sick. When she was first diagnosed, we weren’t sure how to learn about vasculitis. Help came, after we were introduced to the Vasculitis Foundation’s newsletter, which was a helpful resource and one for which we were grateful.
Dr. Alicia Rodriguez-Pla Joins Newly-Created University Of Arizona Vasculitis Center

By John Fries

Alicia Rodriguez-Pla, MD, PhD, MPH, a board-certified internist and board-eligible rheumatologist, has been appointed clinical assistant professor of medicine in the Rheumatology Division of the University of Arizona College of Medicine – Tucson.

In her new role, Dr. Rodriguez-Pla is part of a newly-created Vasculitis Center, a multidisciplinary medical team of specialists, all of whom have vasculitis-related experience and expertise. “We can communicate quickly with each other,” she says, “and we will try to coordinate the care of the patients in the most efficient and optimal way to assure that the best possible care is offered.”

Dr. Rodriguez-Pla earned her medical degree at the Universidad de Navarra in Pamplona, Spain. She also holds a PhD in immunology/rheumatology from the Universitat Autonoma de Barcelona, where she worked in translational and epidemiological research on giant cell arteritis.

Her career took her to the U.S. where she served four years as a visiting research, post-doctoral fellow at The Johns Hopkins University. At Hopkins she continued her research in giant cell arteritis and observed patients at their Vasculitis Center while earning a Master’s degree in Public Health. Her final two years at Hopkins were funded through a Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation (VF) fellowship. After spending a short time practicing medicine in Spain and a stint at Baylor University in Texas working on lupus research, Dr. Rodriguez-Pla moved northeast to serve as a clinical fellow in rheumatology under Paul Monach, MD, then director of Boston University’s Vasculitis Center.

At BU, she and Dr. Monach began a research project to look for biomarkers of disease activity in different types of vasculitis, including giant cell arteritis, eosinophilic granulomatosis with polyangiitis, Takayasu’s arteritis, and polyarteritis nodosa. She also gained clinical experience in scleroderma—another rare autoimmune disease, though not vasculitic.

Dr. Rodriguez-Pla has been interested in vasculitic disorders for many years. “The first patient I saw during clinical rounds in medical school was a woman with Takayasu’s arteritis, and I didn’t know at the time that blood vessels could become inflamed,” she says. “It was then that I decided to become a rheumatologist,” she says.

Dr. Rodriguez-Pla is excited about her new role at the University of Arizona.

“I believe there has been a clear need for a vasculitis center in the southwestern U.S.,” says Dr. Rodriguez-Pla. “Many people from other areas are now moving and retiring to Tucson, and many of them have or will develop vasculitis. They now truly benefit from having a team of doctors interested in—and specializing in—their conditions.”

V-RED 2019, cont.

V-RED 2019 Yields Record Amount of Nominations
In 2018, a total of 42 patients nominated their medical professionals. This year the VF has received more than 50 nominations, and several more weeks remain for submissions.

For Karen Hirsch this level of participation validates the original idea for the V-RED Award.

“We all know that diagnosing vasculitis early is a continuing challenge. There are so many unfortunate stories where patients suffer permanent damage from a late diagnosis or misdiagnosis,” says Hirsch. “Our idea was to turn that around and recognize those who are intervening early and using the award to spread awareness among medical professionals.”

If you would like to nominate a medical professional for this award, visit the 2019 V-RED web page at https://bit.ly/2CZEZ1V.

Nominations will be accepted until March 15, 2019.
Ashley Spencer Refuses to Give In

By Ben Wilson

I’ve said it before, but if you are ever feeling down and out, or are struggling to find daily inspiration (an admitted challenge during the endless winter months), I’d suggest looking no further than the collection of young adults fighting against vasculitis. While each of us have been on unique journeys against this disease, very few of us have gone through what Ashley Spencer, the subject of this edition’s patient profile, has gone through over the past six years.

Ashley’s story is quite possibly the best real-life example I’ve seen of the need for better education of vasculitis among our doctors and hospital systems.

Ashley, a standout student in physical therapy school with a bright future ahead of her, was 22 when she was diagnosed with EGPA. However, the aftermath of her diagnosis was anything but straightforward, and she nearly lost her life on multiple occasions as a result.

While living in the Philadelphia area and struggling to achieve remission, doctors repeatedly denied her requests for new therapies and treatments. This included Nucala, a groundbreaking treatment approved by the FDA in 2018, that has vastly improved the lives of many vasculitis patients (myself included). “They kept telling me I had an imaginary disease,” Ashley says. “I remember the doctors talking outside of my room and actually calling me crazy in front of other people in the hospital.”

After six years of struggles, Ashley had enough. She decided to uproot her life and move to Cleveland, Ohio, in the hopes that the Cleveland Clinic would provide better care.

Fortunately, her conditions have started to improve. Doctors fought with her insurance company to get her approved for Nucala, which has helped her condition immensely and allowed her to begin weaning off methotrexate and steroid treatments. “It’s a legit miracle drug,” she says. “I feel like I have at least part of my life back now.” Despite that, her vasculitis remains active and she has a wealth of side effects that have developed since her diagnosis in 2012, including a blood clot in her heart, that doctors found last summer.

Through it all, Ashley remains optimistic, and now wants to turn her attention towards educating physician groups about EGPA and prevent her experience from happening to anyone else. “I’m so passionate about it because you aren’t crazy, you’re fighting something that is real.”

As a fellow EGPA patient, Ashley’s resolve and determination is unbelievably inspiring. My hope is that we as a community, with Ashley leading the way, can coordinate efforts to better educate doctors and change the discussion (or lack thereof) about vasculitis in hospitals everywhere.

“I’m so passionate about raising awareness because you’re fighting for something that is real.”

Ashley Spencer
California Runner Finds Helpful Support Through VF and Brandon Hudgins

By John Fries

Art Diaz, a 49-year-old married father of two, embodies the southern California lifestyle of health and vitality. A native resident of Garden Grove in Orange County, Art works as a retail manager at Skechers, the lifestyle apparel brand headquartered in nearby Manhattan Beach. An avid runner, Art has spent many hours logging countless miles on local trails.

His running routine was interrupted in August 2017 when he suddenly developed a host of unexpected medical symptoms after a leg injury: blood clots in his legs, shoulder and chest pain, difficulty breathing, dramatic weight loss, and pronounced weakness. He went to Hoag Memorial Hospital Presbyterian in nearby Newport Beach, where, following blood tests that seemed to indicate vasculitis, Art’s cardiologist immediately referred him to rheumatologist Kathy Karamlou, MD. A few more tests later, Dr. Karamlou diagnosed Art as having GPA.

“It happened so quickly,” recalls Art. “Unlike many, I was fortunate to be diagnosed within three weeks. I’d never even heard of vasculitis, but thankfully my doctors were familiar with it. Dr. Karamlou put me on prednisone and Rituxan, and I was off work for three months.”

Since then, Art has been managing his illness and has resumed running. He continues to taper off his medications and recently completed his fourth course of Rituxan. He also found support via the Vasculitis Foundation and, not surprisingly, from elite runner Brandon Hudgins, who, coincidentally, is sponsored by Skechers, Art’s employer.

“When I was first diagnosed, I started doing web searches to learn more,” he says. “That’s how I discovered the VF. I read Brandon’s book, “Going the Distance”, which I found extremely inspirational. I’m looking forward to meeting him at the next VF Symposium.”

“Support is critical,” says Art when asked what advice he’d give to newly diagnosed patients. “It can make you feel alone, but you’re not. Through the VF, you can interact with, not only doctors and other medical professionals, but also many individuals who share similar diagnoses and struggles. We’re there for each other.”

Vasculitis Foundation Membership Campaign – JOIN!

PLEASE FILL OUT FORM COMPLETELY, DETACH AND SEND TO VF OFFICE

I Am Pleased To Support The Vasculitis Foundation Through My Membership Dues.

DUES: _____ $35 U.S. for all members _____ $500 U.S. Lifetime Membership

In addition, I would like to make a tax-deductible gift * of: _____ $45 _____ $60 _____ $75 _____ $100 _____ $150 _____ Other $_______

Enclosed is my Check or Please Bill My Credit Card (circle one). Visa/MasterCard/Discover/American Express

Card #: ______________________________________________________________

Name as listed on Card: ________________________________________________

Signature: ____________________________________________________________

Exp. Date: ____________ Total: $ ______________ Email: ______________________

Name: ________________________________________________________________

Address: _______________________________________________________________

City: ______________________________ State: __________________ Zip: _____________

Country (if outside the U.S.): _____________________________________________

Mail to: Vasculitis Foundation, P.O. Box 28660, Kansas City, MO 64188

The Vasculitis Clinical Research Consortium (VCRC) is the major clinical research infrastructure in North America dedicated to the study of vasculitis. The VCRC has grown to include 18 academic medical centers in the United States and Canada for the conduct of clinical trials.

The VCRC conducts observational cohort studies, biomarker development, studies of genetics and genomics, clinical outcomes research, studies using an online patient registry, pilot clinical projects, and multicentered, randomized clinical trials. Core components of the VCRC include the VCRC Clinical Data Repository, the VCRC Biospecimen Repository, the RDCRN VCRC Patient Contact Registry, the VCRC-NIH Data and Safety Monitoring Board.

**Join The VCRC Contact Registry!**
Research offers no guarantees, but research cannot move forward without your help. Every active role a patient takes may possibly play a part in discovering new groundbreaking research and finding new treatments.

**Participating Institutions:**

- Boston University School of Medicine Vasculitis Center
- Cedars-Sinai Medical Center United States
- The Cleveland Clinic
- Hospital for Special Surgery Vasculitis & Scleroderma Center
- Istanbul University
- The Mayo Clinic College of Medicine
- Mount Sinai Hospital
- Northwell Health
- Oregon Health & Science University
- St. Joseph’s Healthcare, Hamilton
- University of California, Los Angeles Health
- University of California, San Francisco
- University of Kansas Medical Center
- University of Michigan
- University of Pennsylvania
- University of Pittsburgh
- University of Utah

Please visit the VCRC website to join the registry and to review the complete list of all current research studies available for patients to participate in. [https://www.rarediseasesnetwork.org/cms/vcrc/](https://www.rarediseasesnetwork.org/cms/vcrc/)

---

**TAPIR Trial Recruiting Patients**

The Assessment of Prednisone in Remission (TAPIR) Trial has recently expanded its eligibility criteria to enroll patients that have recently taken or are currently taking Rituximab.

**What we are studying:**

The TAPIR trial is a clinical trial for patients with GPA in remission-individuals who had a reduced number of symptoms or no change in GPA symptoms.

The study asks the question, is it more beneficial for patients with GPA to maintain low-dose prednisone intake during remission versus eliminating prednisone intake altogether?

TAPIR aims to find the answer to this question and ultimately establish the most favorable treatment option for patients with GPA in remission.

You can participate in the TAPIR Trial if ...

1. You have been diagnosed with granulomatosis with polyangitis (GPA, also known as Wegener’s granulomatosis)
2. You have needed to take 20 mg or more of prednisone each day at some point in the last 12 months
3. Your current prednisone dose is between 5-20 mg/day
4. You are at least 18 years of age
5. Your treating physician is based in the United States or you can travel to a VCRC Clinical Center

*Other conditions may apply

**How to join the TAPIR trial:**

1. You can participate from the privacy of your own home.
2. You do not have to be seen at a participating medical center to enroll in this study. You can join online and continue to see your own doctor. If you already receive your care from a participating VCRC clinical center, you can talk to your doctor about participating in TAPIR.

Visit [www.TAPIRTrial.org](http://www.TAPIRTrial.org)
Thank you for your gift of $50 or More!

Christy Abele
ABL Creations
Nina Adams and Olaf Westgaard
Michael and Kimberly Ahmed
Jeffrey and Ilene Aidekman
Nita and Ronald Aines
Steve Alexander
Holly Alfano
Nicole and Gary Alger
Allen’s Compressor Service Inc
Rocio Alvarado
Friends at America’s Charities
Thomas Amadio
Anne-Line Anderson
Karen and Joseph Anderson
Nancy Anderson
Margaret Anderson
William Andrews
Lee Appleton
Armonk Lions Club, Inc
Maria Arthur
Jane Ascroft
Norm and Kathy Assmann, Gunning
AT&T Employee Giving Program
Marian Azorr and Rick Criswell
Uma Balasubramanian
Elizabeth and Michael Bald
Cheryl and Buddie Baudree
Bank of America Employee Giving Campaign
Amy Barkin and Claude Jackson
Mary Barnard
Paige and Timothy Barrow
Marjorie Bartels
Heather Bartholomew and Casey Leach
Jeffrey Barton
Louiseet Basa
Frank Basso
Janet Beers
Mary Belissimo
Robert Bennett
Gail Berger
Cindy and Dan Berlin
Howard Berman
Francis Berres
Joseph Betz
Sandeep and Lois Bhatt
Kenneth Binning
Doug Bintlieff and Mimi Carr
Sara and Dean Bisterfeldt

Betty Boan
Elizabeth Boaz
Joan Boddie
Brad and Herlinda Bodkins
Ann Bodnar
Boeing Company Employee Giving Camp
Denis and Debbie Bohn
Sue Botte
Mary Ann Boucher
Denise and Clyde Bowman
David Boyle
Elizabeth Brant, MD
Nancy Brantingham
Rosemary Brechtelsbauer
Dru Brenner-Beck and John Beck
William and Ellen Bridgman
Suzie Broome
Debbi and Larry Brown
Paul Brown
Joy Buchok
Maureen Buckley
Jim and Janohn Bunck
Marcia Burden
Mary Busby
Orazio Buzzu
Rhonda Johnson Byrd and John Byrd
Theresa Cameron
Jim and Jennifer Cantele
Robert and Antonette Caren
Lucille Carey
Christine and William Carroll
M. Yvette Carter
Josephine and Rodolfo Casas
Carol Casey
Christopher Casey
Donald Casey
George Casey, Jr
Nancy and George Casey, Sr
Melinda Casteel
Dino Castellane
Caz Cazanov
Jonathan and Kathryn Chaffee
Roy Chao
Virginia Chapin
Mary Grace Charter
Xenia Chartouni
Mary Lou Chastain
Beverly and Tony F. Cheek
Jay Chernosky
Arnold M. Chonko, MD, FACP
Dan Christian
Mary Ann and Dennis Chrzanski
Clark Construction Co

Mae Clay
Abby Cobey
Blanca Cofino
Lesley and Arnold Cohen
James Coil
Rodalyn Coleman
Annmarie and Reid Collins
Michael Collins
Susan Conrad
Kathleen and Richard Contreras, Sr
Michael Contri and Geralyn Schultz
Ronald and Nancy Cooley
Maggie Cooper
Robert and Nancy Cooper
Rich Coppa
Sonja M. Cornell
Lynn Cox
Dr. Christine Cox Marinelli and Dr. William Marinelli
Justin Curtis
Ted and Carol Cushman
Jennifer Czerwinski
Yumna Daimee
Penny and Jay D’Aleo
John D’Alessandro
Anthony and Nancy Damato
Barbara and Thomas Damm
Sharon Danforth
Lucy Daniels
Nina and Richard Deats
Thomas and M. Candace Decker
Michelle DeHaven
Suzanne and Marcel DePaolis
Mary Ellen Desjardins
James Devenny
Lisa Deverell
Barbara and David DeYoung
Rebecca Dharlingue
Art and Marisol Diaz
Barbara Dietrick
Gretchen and Daniel Dill
Jane and John Dion
Joe and Genie Dixon
Gail Dohrn
David Donald
Maureen Donehey and Dennis Nykkel
Heather and Michael Dotsey
Peter Doukas
Ann Dubore
Vladimir and Inessa Dvorkin
Connie Edwards
Kim and David Edwards
Patricia and William Edwards
Alan and Lollie Eidsness
Grace and Paul Eisen

Marcia and Richard Eisenberg
Seth Eliot
Leon Ellin
Mary Lynn and Paul Ellis
David and Lisa Erickson
Abby Ershow
Pete Espinoza
John Eustace
Shelly Evans
Susan Evans
Christine and Paul Falzone
Rosalyn Farrell
John and Donna Marjean Fawcett
Joseph and Michele Fazio
Christine Featherstone
H. Glenn Fee, III and A. Lynn Fee
Bill and Marilyn Fenton
Christine and Anthony Ferroni
Ed and Maureen Field
Ilya and Michelle Finkelsteyn
Lauren Finkelsteyn
Melanie Fischer, James and Joyce Clark
Judith Ford
Colleen Forestal
Daniel Forkosh
Janie and Robert Frahm
Robert and Koreen Francisco
Joseph Franklin
Mike Frauenhoffer
Bart Freeman, Esq
Carol Freeland
John Freeman
Frederick Frein
Mark Freudenthal
Jane and Claude Frymark
Keith and Carolyn Furlong
Mark Gaisford
Beverly and Armand Gandara
Eric and Kathleen Gardze
Ken and Elizabeth Garvey
Dennis Gaushell
Dave Gavett
Dr. and Mrs. Don Gebhart
W. Mark Geldmeier
Harry and Jill Gibson
Robert and Cheryl Gibson
Dennis and Connie Glueckert
Connie Goins
Kimberly and Tim Golbuff
Patti Goodwin
Jennifer Gordon, PhD
Maureen Gorham
Steve and Mary Gorski
Howard and Roberta Goss
Judith Gottesfeld
Hedy Governa
Donors, cont.

Ellen Grabow
Michael Grabowski
Katie and Robert Graham
William A. Graham, IV
Henry and Eugenia Green
Family Foundation
Jim Greene
Jeff Grel
Louis Grimaldi
Jane Groos
Lenore Grossman
JoAnn and John Gruben
Michael Gunderson
Anna Gurevich
Paula A. Gurley
Phillip Haase
Randy Haberman
Brett Hack Vasculitis Charities
Andrew Hafenscher
Ida Hakkarinen
Dennis and Ruth Hale
Betty and Gale Harp
Jeff Hartman
Timothy Harvey
Kathleen Haslett
Laura Hatch
Denise Terry Hayden
Judy Hayes and Hugh Rhine
Joseph and Molly Haywood
Robert Hazard
Gregory Heinlein
Judye and Richard Heitfield
Kathleen Henrich
Bob Henriksen
Elizabeth Herlihy
Larry and Marlene Hershfield
Patricia and Thomas Hessler
George and Carolyn Heyne
Stanley and Amy Heyse
Brook and Keith Hickle
Jane Hill
Hilton Family
Kenneth and Margaret Hilton
Rob and Debbie Hinderliter
Jon and Dorothy Hinkle
Arlene Gloria Hirsch
Ellen Hirsch
Karen and Dan Hirsch
Michael Hirsch
Courtney Hodock
Chris Hoer
Dr. Gary and Mrs. Diane Hoffman
John Hollyday
Schelley Hollyday
J. Elaine Holmes
Hoover Financial Advisers
Laurie and Johnie Hope
Janice and Dwight Howard
Beth Howe
Emily and Calvin Hudgins
Bob and Garlanda Hughey
Myrna Hunt
Susan and Thomas Hurlebaus
IBM Employee Svc. Ctr.
ITW Foundation 3for1 Matching
Carey and Mary Ellen Jacobson
Marilyn and Ken Jacobson
Aqueela and Shahnwaz Jaffer
Victor and Brenda James
Phil and Donna Jarvis
Barbara Jensen
Ellie Jeppesen
Irene Jeyowski
J.K. Group Inc.
Richard Johnson
Sally Johnson
W.E. Johnson
Paula Jones
Richard and Suzanne Jones
Daniel Jordan
Paolo Jory
JP Morgan U.S. Equity Fund
Phyllis Judd
Misty Justus-Baker
Chris and Adele Kalogeris
Beverly Kambe
Celia Kang
Susan and John Karas
Mitchell Karsch
Jeremy Keehn
Donald Keeley
Barbara Kelley
Patricia Kelley
Nancie Kennedy
Lillian and John Kerchner
Christine and Larry King
Christine and Anthony Kinney
Prof. M.B. Kirkham
Donald and Carolyn Kliger
Eric Knieging
Sharan Knoll
Gayle Knoll
Linda and James Kolberg
Phyllis Korpan
Heather and Ara Krafian
Joyce A. Kullman
Dianne and Robert Kusek
Jacob Kysar
L & S Demo Recycling Co Inc
Nancy Landreth
Carolyn and Charles Landry
Anne Marie Lane
Mary Lane
Linda Lang
Kimberly and Randall Langbehn
Brad and Lori Larson
Esther Jean Larson
Phyllis and Fred Lasky
Samantha Lasky
Alfred and Sandra Latey
John Latoski
Gilbert Lauhoff
Michael and Elizabeth Lauhoff
Mark and Janice Lauristen
Ray Lauzon
Antonio Laverghetta, Jr
Brenda and Randall Law
Elizabeth and Martha Lawrence
Don and Ruth Ann Laws
Voni Lawson
Gail and Robert Lee
E. Jane Leonard
Harry Letaw
Jodi Levin
Meta and Larry Levin
Stuart and Amanda Levine, MD
Jen Levithan
Eric Lewis
Richard A and Rosalie Lewis, MD
Dan Liberg
Kent Vander Linde
Kim Lint
Karen and John Lipchik
Joan, Stuart and Ken Liss
Loren and Barbara Littlefield
Nancy Logan
Beatriz Loiederman
Bernie and Jocelyn Lorenz
Elizabeth Lowder
Agnes and LeRoy Luft
David and Rebecca Lyons
Nancy Lysandrou
Stephanie MacDonald
Daria Mace
Brian and Judy Madden
Susan Manalli
Naomi Marco Manelis and Joseph Manelis
Margaret Marasco
Michael and Denise Marchesani
Randall Marek
Valerie Martinez
Janelynne Massey
Katherine Mayer
Nancy McCaffrey
James McCardell and Pamela Wood
Lorri McCourt-O’Donnell
Diana and Larry McDevitt
Lisa McFarlane
Jill McGlenn
Susan McGourty
Mike McGregor
Jim and Deb McGuire
Elizabeth McLaughlin
Michael McLaughlin
Paula McLemore
Sean McNulty
Rhonda Mefford
Chris Meier
Cindy and Terence Meier
Stacey Menheer
Peter Merkel, MD, MPH
Kathy Meyer
Judith Milks
Jeanne Miller
Crystal and Bruce Miller
Dr. and Mrs. Wayne Miller
Gloria Mir
Nancy Miron
Jorge and Kim Molina
Sally and Peter Morin
Kathy and Rick Morris
Dennis Muraro
Courtney Myers
Ray and Ann Naegle
Sarah Nagle, MD
Douglas and Tina Nardella
Nationwide Foundation
Ralph Neely
Tom and Nancy Neilson
Virginia Nelson
Ruthe Nepf
Network for Good
Dan and Carol Neuman
Neumann/Smith Architecture
Leslie and Michael Nickerson
Nancy Nightingale
Mary Ninos
Deborah Nonberg and Mildred Sudarsky
Ted and Linda Norbits
Eric and Anne Nordell
Dolores Nordstrom
Sandy and Bob Nye
Karyn and Richard O’Donnell
Bernadette and James Olsen, Sr
Thomas O’Malley
Martin and Joyce Oppenheimer
Anthony and Janine Papa
Donors, cont.

Patricia Papadopoulos, MD
Daria Carr
Jean Parr
Kathleen Parr
Jart and Marli Pasternak
Kirk Paulsen
John Perry
Terry Perry
Carrie Pierson
Jean Platt
Margaret Plummer
PMA Companies
Diane Pokrajac
Michael Poliner
Maria Pollock
Jack and Bernice Pope
Judith Powers
MaryAnn and John Powers
Craig Pratt
Dusty Prentiss
John and Kathy Presner
Cecilia Preston
Peter Prinsen
Kristen and Robert Privette
Robert Pucci
Daniel Puelen
Becky and Bruce Pulitini
Thomas Pyra
Thomas and Mary Quinn
Ruth Radcliffe
Karen Ramen
Mary Beth and Tony Randall
Susan Rankin
Phil Rath
Joseph Rayburn
William Reardon
Andrew Reed
Ellen and Bob Rehm
Amy Reitz
Bobby Ress
Dario and Kathrin Rexin
Janet Rhodes
Shane Riccio
Joann Rice
Nina Richman
Cathy Ridenour
Nancy and Thomas Ridley
Kimberly Rockwell
Lynn Roddy
Raquel Rodriguez
Ronald Rogers
Linda Rohrer
Margaret Romigh Barnhart
Darise Ronning
Dr. and Mrs. Steven Rosenbaum
Priscilla Roslyn
Geri and Don Serot
Barbara and Robert Rottman
Jeffrey Rubenstein
Rosalind Rubler
David and Nikki Rust
Katherine Rypinski
Margaret and Norman Sams
Ian and Corinne Sanderson
Roy Saper
Suzann Sass
Rajaram Satyanarayanan
Rosemary Saunders
McKenna and Sharon Sax
Scattered Seeds
Garden Club
J. Pete Schaeffer
Magda Schaffer
Eileen and William Scheffer
Sondra Schmidt
Amanda and Daniel Schneider
William and Maureen Schnier
Juliet Schoeberlein
Janice Scholl
Doris Schraft
Gail Schultz
Jon and Katherine Schumacher
James Schwall
Rachel Schwartz
Kenneth Schweda
Emma Scott
Lon and Brenda Seeger
Deborah Seeley
Paul and Dee Selheim
Helen Sells
Debbie and Anthony Selover
Mary Seubert
John Seward
Philip Shama and Winnifred Shama
Wendy Shanker
Stuart Shanklin and Janet Fernandez-Shanklin
Donna and Mike Sharp
Carol Shea
Rachel Shelton
William Short
Martha Shreiner
Bella Shupac
Sandra Shute
Cynthia Sievers
Sylvia and Anthony Sikorski
Nancy Simas
Virginia and Mark Simpson
Tamara and Daniel Skvir
Linda and Mark Slater
Linda Smith
Linda and Robert Smith
Peter Smith
Kenneth Snodgrass
Gail and Sanford Solomon
Frank Sosler
Lisa and Ivan Spencer
Anne and Carmine Sprio
Antoine Sreih, MD
Joseph and Barbara Staknis
Donal and Anne Staples
John Starnes
Kathleen Steele
Jolinda Stephens
Joan and Marx Sterne
Ashley Stewart
Cynthia Stites and Donald Nagle
Dale and Annie Stoyanoff
Daniel and Agnes Sughrue
Gillian Svendsen
Patty and Bob Swanson
Carol and Myrna Swart
David Sweigard
Brenda Tabler
Jean Talarico
Karen Taylor
Trudy Taylor
Shelly Telford
Bonnie and Don Thomas
Margaret Thomas
Thomas & Engelmann Wealth Management
Carol Thompson
Beth Threath
Thrivent Funds
Joanne Tibbetts
Michael and Deborah Tinnman
Beverly Torelli
Mary Torgler
Richard and Rebecca Torossian
Kelly Trefil
Raitis and Vija Treibergs
Eric and MontanaTroyer
Steven Tryon and Catherine Ridenour
Gloria Tuibs
Tudor Investment Corporation
Sophia Twiss
Linda Uffenheimer
United Way of Berkshire
United Way of Buffalo and Erie County
United Way of Greater Greensboro, NC
United Way of Greater Kansas City, MO
United Way of King County
United Way of Los Angeles
United Way of Miami Dade
United Way of the Virginia Peninsula
Tere Valcarcel
Debbie Van Wert
Jim and Kayla Vanderbilt
Suzanne Vandiver
Tish and Dominic Varraveto
John and Wilma Velez
Annika Victoria
Carol Vidal
Matt Volz
Travis Vruggink
Inez and Barry Waddle
Jason and Lisa Wadler
Larry Wahrer
Ronald Waite
Cindy Wall
John and Donna Wall
Michael and Victoria Wallace
Wendy Wallace
Kevin Walsh
Jeffrey Watts
Robert L. and Robin Wedell
Alan and Judith Wertheimer
Vicky Wertman
Lori Westerhold
Joanna and Kenneth White
Mary Jo Whitley
Chuck Wickersham
Rudy and Margie Widmann
Kristi Williams
Charles W. Wilmarth, Jr
Karen Wilson
Denise Wimett
Andrew and Susan Wirth
Vicky Wixon
Brian and Karin Woglam
Muriel and Harvey Wollner
Bill Woodworth
Linda and Kim Wortman
Kathie Wunderlich
Bill Wyant
Brad and Debbie Yates
Paula Yates
Gary Young
Alfred and Deborah Yudes
Steven Zakolski
Charles Zammit

VF Medical and Scientific Advisory Board

Abdo, Nabil, I., MD, PhD, FACP (Retired)
University of Missouri Rheumatology/Immunology
Kansas City, Missouri

Allen, Nancy B., MD
Duke University Rheumatology and Immunology
Durham, North Carolina 919.613.2243

Archer, Amy M., MD, PhD
Northwestern Vasculitis Clinic Rheumatology
Chicago, Illinois 312.695.8628

Benseler, Susanne (Susa), MD, PhD
Alberta Children’s Hospital Research Institute Pediatrics/Rheumatology
Nashville, Tennessee 603.653.3830

Byram, Kevin, MD
Vanderbilt Vasculitis Clinic Rheumatology and Immunology
Nashville, Tennessee 615.322.1900

Cacoub, Patrice, MD
Hospital Universitaire Pitie Salpetriere Charles Foix Rheumatology
Paris, France 01.42.17.76.22

Capizzi, Stephen A., MD
Duke University Pulmonary Medicine/Critical Care
Durham, North Carolina 919.613.2243

Chung, Sharon, MD, MAS
University of California San Francisco (USF) Health Vasculitis Clinic Rheumatology
San Francisco, California 415.514.1673

Cid, Maria Cinta, MD
Clinic Barcelona, Hospital Universitari Systemic Autoimmune Diseases
Barcelona, Spain 93.227.54.00

Dooley, Mary Anne, MD
WakeMed Physician Practice Rheumatology
Raleigh, North Carolina 919.235.6454

Dua, Anisha, MD, MPH
University of Chicago Medicine Rheumatology/Vasculitis
Chicago, Illinois 773.702.1000

Falk, Ronald J., MD
University of North Carolina (UNC) Nephrology and Hypertension
Chapel Hill, North Carolina 984.974.5706

Fervenza, Fernando C., MD, PhD
Mayo Clinic Nephrology
Rochester, Minnesota Appointments: 507.538.3270

Flores-Suárez, Luis Felipe, MD, PhD
Academia Nacional De Medicina De Mexico Rheumatology
Mexico City, Mexico 55.5519.8432

Forbess, Lindsay, MD, MSC
Cedars Sinai Medical Center Internal Medicine/Rheumatology Los Angeles, California 1.800.233.2771

Garrity, James A., MD
Mayo Clinic Ophthalmology
Rochester, Minnesota 507.538.3270

Geetha, Duvuru, MBBS, MD
Johns Hopkins Medicine Peritoneal Dialysis and Hemodialysis
Baltimore, Maryland 410.955.0670

Gota, Carmen E., MD
Cleveland Clinic Main Campus– Fibromyalgia Clinic Rheumatology and Immunologic Disease
Cleveland, Ohio 866.320.4573

Grayson, Peter, MD, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Fellowship Program, Systemic Autoimmunity Branch
Bethesda, Maryland 301.827.9187

Haj-Ali, Rula, MD (Adults only)
Cleveland Clinic Main Campus Rheumatology/Immunology
Cleveland, Ohio 866.320.4573

Hashkes, Philip J., MD, MSC
Pediatric Day Hospital at Sharee Zedek Medical Center Pediatric Rheumatology Unit Jerusalem, Israel 972.2.6555307

Hauser, Thomas, MD
IZZ Immunologie-Zentrum Zurich Allergology/Immunology, General Internal Medicine
Stampfenbachplatz, Zurich, Switzerland 044.434.10.00

Heeringa, Peter, PhD
University Medical Center Groningen (UMCG) Vasculitis
Groningen, Netherlands 31.50.361.0789

Hellmann, David Bruce, MD, MACP
Johns Hopkins Bayview Medical Center Department of Medicine
Baltimore, Maryland 410.550.6193

Jayne, David, MD
Addenbrooke’s Hospital Vasculitis and Lupus Clinic Cambridge, United Kingdom 01.223.217259

Kermani, Tanaz, MD
University of California, Los Angeles (UCLA) Vasculitis Program/Rheumatology
Santa Monica, California 310.882.6350

Khalidi, Nader, MD
St. Joseph’s Healthcare Hamilton McMaster University, Hamilton Rheumatology
Hamilton, Ontario, Canada 905.522.1155 Ext. 33260

Khasnis, Atul, MD, MS
Georg apoptosis Research Clinic
Newnan, Georgia 678.889.7900

Knight, Jason Scott, MD
Michigan Medicine Rheumatology Clinic University of Michigan Rheumatology/Internal Medicine
Ann Arbor, Michigan 888.229.3065

Koenig, Michael, MD
University of Utah and Salt Lake City Veterans Affairs Medical Center Vasculitis Clinic Salt Lake City, Utah 801.581.7724

Koster, Matthew, J., MD
Mayo Clinic Rheumatology
Rochester, Minnesota 507.538.3270

Lally, Lindsey, MD
Weill Cornell Medical College Hospital for Special Surgery Rheumatology
New York, New York 212.606.1000

Langford, Carol A., MD, MHS, FACP
Cleveland Clinic Main Campus Rheumatology/Immunology
Cleveland, Ohio 216.444.2606

Lebovics, Robert S., MD, FACS
Mount Sinai Hospital Mount Sinai Doctors Otolaryngology
New York, New York 212.262.4444

Lee, Augustine S., MD
Mayo Clinic Critical Care/Pulmonology Jacksonville, Florida 904.953.0853

Levine, Stuart M., MD, FACP
MedStar Harbor Hospital MedStar Health Baltimore, Maryland 855.633.8880

Lin, Yih Chang, MD
University of Southern Florida (USF) Health Rheumatology
Tampa, Florida 813.974.2201

Lorenz, Robert R., MD, MBA, FACS
Cleveland Clinic Main Campus Otolaryngology, Head and Neck Surgery
Cleveland, Ohio 866.320.4573

Mahr, Alfred, MD, PhD
Assistance Hopitaux Publique De Paris Internal Medicine Paris, France +33.0.1.42.49.93.35

Maksimowicz-McKinnon, Kathleen, DO
Henry Ford Health System Rheumatology
Detroit, Michigan 800.436.7936

Matteson, Eric L., MD (Retired)
Mayo Clinic Faculty, Emeritus Rheumatology/Internal Medicine Rochester, Minnesota 507.284.2511

Maz, Mehrdad, MD
The University of Kansas Medical Center Allergy, Clinical Immunology and Rheumatology
Kansas City, Kansas 816.673.2124

Merkel, Peter A., MD, MPH
Perelman School of Medicine, University of Pennsylvania Penn Medicine Rheumatology, Biostatistics and Epidemiology Philadelphia, Pennsylvania 800.789.7366
VF Medical and Scientific Advisory Board

Rodriguez-Pla, Alicia, MD, MS, FRCPI
Saint Vincent's University Hospital Centre for Arthritis and Rheumatic Diseases
Rheumatology
Dublin, Ireland
01.221.4000

Monach, Paul, MD, PhD
Brigham and Women's Hospital
Rheumatology
Boston, Massachusetts
617.732.5766

Nachman, Patrick, MD
University of Minnesota
Renal Diseases/Hypertension
Minneapolis, Minnesota
612.273.8383

Pagnoux, Christian, MD, MSC, MPH
Mount Sinai Hospital/Sinai Health System
Rheumatology
Toronto, Ontario, Canada
416.586.4800 Ext. 8549

Senior, Brent, A., MD, FACS, FARS
University of North Carolina (UNC)
Otolaryngology/Neurosurgery
Chapel Hill, North Carolina
984.974.6484 Option 2

Seo, Philip, MD, MHS
Johns Hopkins Bayview Medical Center
Rheumatology
Baltimore, Maryland
443.997.1552

Silva, Francisco, L., MD, MS
Clinica Alemana de Santiago
Rheumatology
Santiago, Chile
562.220.1111

Spalding, Steven J., MD
Akrorn Children's Hospital
Pediatric Rheumatology
Akrorn, Ohio
330.543.8574

Specks, Ulrich, MD
Mayo Clinic
Pulmonary and Critical Care Medicine
Rochester, Minnesota
507.266.0413

Sawalha, Amr, MD
University of Michigan Medical School
Michigan Medicine
Rheumatology/Internal Medicine
Ann Arbor, Michigan
888.229.3065

Senior, Brent, A., MD, FACS, FARS
University of North Carolina (UNC)
Otolaryngology/Neurosurgery
Chapel Hill, North Carolina
984.974.6484 Option 2

Seo, Philip, MD, MHS
Johns Hopkins Bayview Medical Center
Rheumatology
Baltimore, Maryland
443.997.1552

Silva, Francisco, L., MD, MS
Clinica Alemana de Santiago
Rheumatology
Santiago, Chile
562.220.1111

Spalding, Steven J., MD
Akrorn Children's Hospital
Pediatric Rheumatology
Akrorn, Ohio
330.543.8574

Specks, Ulrich, MD
Mayo Clinic
Pulmonary and Critical Care Medicine
Rochester, Minnesota
507.266.0413

Sawalha, Amr, MD
University of Michigan Medical School
Michigan Medicine
Rheumatology/Internal Medicine
Ann Arbor, Michigan
888.229.3065

Spera, Robert, MD
Weill Cornell Medical College Hospital for Special Surgery (HSS)
New York Presbyterian Hospital and Weill Cornell Medical Center
Rheumatology
New York, New York
212.860.4000

Springer, Jason, MD
University of Kansas Medical Center
The University of Kansas Physicians
Allergy, Immunology and Rheumatology
Kansas City, Kansas
913.588.1227

Sreih, Antoine, MD
Penn Rheumatology Perelman
Rheumatology
Philadelphia, Pennsylvania
800.789.7366

Stone, John H., MD, MPH
Massachusetts General Hospital
Rheumatology Associates
Rheumatology/Internal Medicine
Boston, Massachusetts
617.726.7938

Twilt, Marinka, MD, PhD
Cumming School of Medicine, Alberta Children's Hospital
Paediatrics
Calgary, Alberta, Canada
403.955.7480

Villa-Forte, Alexandra, MD, MPH
Cleveland Clinic Main Campus
Rheumatology/Immunology
Cleveland, Ohio
866.320.4573

Warrington, Kenneth J., MD
Mayo Clinic
Rheumatology/Internal Medicine
Rochester, Minnesota
507.538.3270

Weyand, Cornelia, MD, PhD
Stanford University School of Medicine
Immunology/Rheumatology
Stanford, California
650.723.6961

Weisman, Michael H, MD
Cedars-Sinai Medical Center
Rheumatology
Los Angeles, California
800.233.2771

Yazici, Yusuf, MD
New York University (NYU)
Langone Medical Center
Rheumatology
New York, New York
646.501.7400

Yeung, Rae S.m., MD, PhD, FRCPAC
The Hospital for Sick Children
The Research Institute
The University of Toronto
Paediatric Rheumatology
Toronto, Ontario, Canada
416.813.8883

Sawalha, Amr, MD
University of Michigan Medical School
Michigan Medicine
Rheumatology/Internal Medicine
Ann Arbor, Michigan
888.229.3065

Spera, Robert, MD
Weill Cornell Medical College Hospital for Special Surgery (HSS)
New York Presbyterian Hospital and Weill Cornell Medical Center
Rheumatology
New York, New York
212.860.4000

Springer, Jason, MD
University of Kansas Medical Center
The University of Kansas Physicians
Allergy, Immunology and Rheumatology
Kansas City, Kansas
913.588.1227

Sreih, Antoine, MD
Penn Rheumatology Perelman
Rheumatology
Philadelphia, Pennsylvania
800.789.7366

Stone, John H., MD, MPH
Massachusetts General Hospital
Rheumatology Associates
Rheumatology/Internal Medicine
Boston, Massachusetts
617.726.7938

Twilt, Marinka, MD, PhD
Cumming School of Medicine, Alberta Children's Hospital
Paediatrics
Calgary, Alberta, Canada
403.955.7480

Villa-Forte, Alexandra, MD, MPH
Cleveland Clinic Main Campus
Rheumatology/Immunology
Cleveland, Ohio
866.320.4573

Warrington, Kenneth J., MD
Mayo Clinic
Rheumatology/Internal Medicine
Rochester, Minnesota
507.538.3270

Weyand, Cornelia, MD, PhD
Stanford University School of Medicine
Immunology/Rheumatology
Stanford, California
650.723.6961

Weisman, Michael H, MD
Cedars-Sinai Medical Center
Rheumatology
Los Angeles, California
800.233.2771

Yazici, Yusuf, MD
New York University (NYU)
Langone Medical Center
Rheumatology
New York, New York
646.501.7400

Yeung, Rae S.m., MD, PhD, FRCPAC
The Hospital for Sick Children
The Research Institute
The University of Toronto
Paediatric Rheumatology
Toronto, Ontario, Canada
416.813.8883

VF Medical and Scientific Advisory Board

In Memoriam

Thank You to all those who made donations to the VF in memory of a loved one.

Fred Charles Adam
Jeff Arthur
John M. Avery
George P. Barker
Lucinda Basso
Betty Beard
Edward Harold Bennett
Lorraine Bernstein
Marlene Berres
Joseph T. Buckley
Ryan Bunck
Edward Burke
Pamela Carlson
Phillip Carr
Christopher Collins
Frank Connely
Michael D. Curley
Kathleen Cushmore
Barbara Daggett
Nancy DeVenny
Ruth Carol Dunn
Agnes Esper
Dolly Espinoza
Vince Filippello
Mary Louise Foley
David Ford
Bob Frank
John E. Gaisford
Joann Gregg
Gene Gronseth
Charles Hafer
Maryanne Heiser
Mildred Herbstman
Barbara & Peter Hochreiter
Jack Hogg
Jean Hughes
Leo Jeyowski
Douglas Kelley
Mary E. Kirkham
Glenn Kullman
James Langbehn
Karen Latoski
Marie Mastandrea
Harry McFarlane
Don Medaglia
Jorge Mir, Jr
George Miron
Willie Naulls
Eileen O’Leary
Mary Pantaleo
Nicholas Pascente
Rose Peasley
Ilya Peckerman
Harold Ramis
Saturn Rao
Carol Reitz
Robert Rhodes
Edward Rosendahl
Robert Sahs
Harm Schluter
Karen Schweda
Heather Seaton
Kathleen Sharkey
Galen Shreiner
Robert Gary Simas
Gail F. Smith
Harlan Sylvan
Brittanie Tubbs
Patricia Ann Ulshafer
Ernest Widmann
Virginia “Ginny” Kay York
Vivian Zaruba

Save the date!

VF Calendar of Events • 2019

Go to our online calendar with the latest information about our upcoming events: Vasculitis Foundation
www.vasculitisfoundation.org/events/

February 28, 2019
International Rare Disease Day

March 5, 2019
Allison Lint and Violin For Vasculitis: Music and Medicine
Pritzker School of Medicine
924 E 57th Street Suite, Room 109, Chicago, Illinois
5:00 p.m. - 6:30 p.m.
violinforvasculitis.org

March 9, 2019
VF - Mayo Clinic Arizona Patient Conference
Waugh Auditorium
5777 East Mayo Boulevard, Phoenix, Arizona
8:30 a.m. - 3:30 p.m.

April 5, 2019
Violin For Vasculitis: Alabama
violinforvasculitis.org

April 7-10, 2019
The 19th International Vasculitis & ANCA Workshop For Physicians and Researchers
Loews Hotel, Philadelphia, Pennsylvania
vasculitis2019.org

April 13, 2019
North Carolina/Raleigh Chapter Vasculitis Support Group Meeting
UNC Wellness Center at Meadowmont in Chapel Hill 100 Sprunt Street Chapel Hill, North Carolina 27517
10:00 a.m. - 2:00 p.m.
Contact: Jill Powell, Administrator – Vasculitis Support Group Jill_powell@med.unc.edu

April 13, 2019
Kansas City Chapter Meeting
BEST Conference Center, Room 125
University of Kansas Edwards Campus
12600 Quivira Road, Overland Park, KS 66213

May 1-31, 2019
Vasculitis Awareness Month

May 18, 2019
Spaghetti Western Dinner
37811 176th Ave S.E., Auburn, WA 98092

July 19-21, 2019
International Vasculitis Symposium